BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.5%

Neg 0% Neu 87.5% Pos 0%

BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.

Comments

No comments yet. Be the first!